electroCore, Inc.
NASDAQ:ECOR

Watchlist Manager
electroCore, Inc. Logo
electroCore, Inc.
NASDAQ:ECOR
Watchlist
Price: 16.26 USD -7.19% Market Closed
Market Cap: 106.5m USD
Have any thoughts about
electroCore, Inc.?
Write Note

electroCore, Inc.
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

electroCore, Inc.
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
electroCore, Inc.
NASDAQ:ECOR
Interest Income Expense
$574k
CAGR 3-Years
N/A
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Interest Income Expense
-$364m
CAGR 3-Years
1%
CAGR 5-Years
10%
CAGR 10-Years
-15%
Boston Scientific Corp
NYSE:BSX
Interest Income Expense
-$564m
CAGR 3-Years
N/A
CAGR 5-Years
2%
CAGR 10-Years
-11%
Stryker Corp
NYSE:SYK
Interest Income Expense
$127m
CAGR 3-Years
23%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Abbott Laboratories
NYSE:ABT
Interest Income Expense
-$247m
CAGR 3-Years
21%
CAGR 5-Years
17%
CAGR 10-Years
-12%
Intuitive Surgical Inc
NASDAQ:ISRG
Interest Income Expense
$315.7m
CAGR 3-Years
54%
CAGR 5-Years
21%
CAGR 10-Years
39%
No Stocks Found

electroCore, Inc.
Glance View

Market Cap
105.8m USD
Industry
Health Care

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).

ECOR Intrinsic Value
18.49 USD
Undervaluation 12%
Intrinsic Value
Price

See Also

What is electroCore, Inc.'s Interest Income Expense?
Interest Income Expense
574k USD

Based on the financial report for Sep 30, 2024, electroCore, Inc.'s Interest Income Expense amounts to 574k USD.

What is electroCore, Inc.'s Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-15%

Over the last year, the Interest Income Expense growth was 30%.

Back to Top